Market Cap 8.60M
Revenue (ttm) 0.00
Net Income (ttm) -82.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.10
Volume 1,562,500
Avg Vol 4,676,562
Day's Range N/A - N/A
Shares Out 44.95M
Stochastic %K 0%
Beta 0.45
Analysts Strong Buy
Price Target N/A

Company Profile

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K....

Industry: Biotechnology
Sector: Healthcare
Phone: 949-396-6830
Address:
3001 Daimler Street, Santa Ana, United States
Picklerinthekitchen
Picklerinthekitchen Jul. 30 at 2:58 PM
$NKGN NKGen Biotech (NKGN) Troculeucel is a first-in-kind, autologous, non-genetically modified NK cell product with significantly increased cytotoxicity and over 90% activating receptor expression that can be consistently produced from any donor. Preclinical and clinical trial data on the effect of troculeucel from two Phase 1 studies were presented to highlight the mechanism of action and confirmatory biomarker data from 13 patients with Alzheimer’s disease. Troculeucel was found to exhibit over 99% DNAM-1 and NKG2D expression, by which NK cells recognize and engage autoreactive T cells while sparing resting T cells, which do not express these ligands. In vitro studies demonstrated that troculeucel was selectively activated in the presence of activated T cells, as evidenced by increased interferon-gamma production, These findings suggest that troculeucel may reduce neuroinflammation by preferentially eliminating autoreactive T cells while preserving non-pathogenic resting T cells.
1 · Reply
GoldGhost
GoldGhost Jul. 29 at 9:40 PM
1 · Reply
Slowgallop
Slowgallop Jul. 29 at 7:03 PM
$NKGN OK. Did more DD. Was not aware that NKGN filed for bankruptcy. Explains everything. Investment firms must follow protocol. When NKGN is qualified to trade again it will be reinstated accordingly. Meantime must be patient...please accept my sincere apology to this board. Truth humbles ego! Thank you, GoldGhost, for your lead! Wish NKGN, AD patients, and Investors a successful 2025!
2 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 29 at 6:40 PM
$NKGN very disappointed the way this has played out
0 · Reply
yup999
yup999 Jul. 29 at 6:13 PM
$NKGN NOT FEEDING THE BEARS...SIMPLY. DO YOUR OWN #DD! ( DUE DILIGENCE)
0 · Reply
yup999
yup999 Jul. 29 at 6:02 PM
$NKGN https://stockscan.io/stocks/NKGN/forecast
0 · Reply
yup999
yup999 Jul. 29 at 5:59 PM
0 · Reply
yup999
yup999 Jul. 29 at 5:58 PM
0 · Reply
yup999
yup999 Jul. 29 at 5:58 PM
0 · Reply
yup999
yup999 Jul. 29 at 5:58 PM
0 · Reply
Latest News on NKGN
No data available.
Picklerinthekitchen
Picklerinthekitchen Jul. 30 at 2:58 PM
$NKGN NKGen Biotech (NKGN) Troculeucel is a first-in-kind, autologous, non-genetically modified NK cell product with significantly increased cytotoxicity and over 90% activating receptor expression that can be consistently produced from any donor. Preclinical and clinical trial data on the effect of troculeucel from two Phase 1 studies were presented to highlight the mechanism of action and confirmatory biomarker data from 13 patients with Alzheimer’s disease. Troculeucel was found to exhibit over 99% DNAM-1 and NKG2D expression, by which NK cells recognize and engage autoreactive T cells while sparing resting T cells, which do not express these ligands. In vitro studies demonstrated that troculeucel was selectively activated in the presence of activated T cells, as evidenced by increased interferon-gamma production, These findings suggest that troculeucel may reduce neuroinflammation by preferentially eliminating autoreactive T cells while preserving non-pathogenic resting T cells.
1 · Reply
GoldGhost
GoldGhost Jul. 29 at 9:40 PM
1 · Reply
Slowgallop
Slowgallop Jul. 29 at 7:03 PM
$NKGN OK. Did more DD. Was not aware that NKGN filed for bankruptcy. Explains everything. Investment firms must follow protocol. When NKGN is qualified to trade again it will be reinstated accordingly. Meantime must be patient...please accept my sincere apology to this board. Truth humbles ego! Thank you, GoldGhost, for your lead! Wish NKGN, AD patients, and Investors a successful 2025!
2 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 29 at 6:40 PM
$NKGN very disappointed the way this has played out
0 · Reply
yup999
yup999 Jul. 29 at 6:13 PM
$NKGN NOT FEEDING THE BEARS...SIMPLY. DO YOUR OWN #DD! ( DUE DILIGENCE)
0 · Reply
yup999
yup999 Jul. 29 at 6:02 PM
$NKGN https://stockscan.io/stocks/NKGN/forecast
0 · Reply
yup999
yup999 Jul. 29 at 5:59 PM
0 · Reply
yup999
yup999 Jul. 29 at 5:58 PM
0 · Reply
yup999
yup999 Jul. 29 at 5:58 PM
0 · Reply
yup999
yup999 Jul. 29 at 5:58 PM
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 29 at 5:27 PM
$NKGN stock can’t go up if it can’t be purchased
0 · Reply
Slowgallop
Slowgallop Jul. 29 at 4:14 PM
$NKGN More Fidelity Investment policy re: trading NKGN: "TC9056) Opening transactions for this security are not currently permitted due to its Expert Markets designation and/or the risk associated with the security." Looks like Fidelity is fencing this off... Anyone on this board aware of a way to purchase NKGN shares?
2 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 29 at 3:47 PM
$NKGN the better the news the further it falls.
0 · Reply
Slowgallop
Slowgallop Jul. 29 at 3:44 PM
$NKGN Fidelity Investstments: Error (TC9052) Opening transactions for this security are not currently permitted due to limited company information and/or the risk associated with the security. Never in my 30+ years of trading have I ever encountered anything like this... An investment company arbitrarily controlling free trade dynamics... Anyone else on this board using a different investment company running into the same problem? Please advise. 😕
1 · Reply
Abdullah5566
Abdullah5566 Jul. 28 at 8:10 PM
$NKGN I noticed the stock is not moving today and on Friday as well (No volume) !!! with big news this must be rocket
2 · Reply
junglezoo
junglezoo Jul. 28 at 6:18 PM
$NKGN amazing
0 · Reply
RupertDCat
RupertDCat Jul. 28 at 2:21 PM
$NKGN https://www.stocktitan.net/news/NKGN/nk-gen-biotech-presents-troculeucel-mechanism-of-action-with-keahq2cy2nxo.html
0 · Reply
PDTstockOwl
PDTstockOwl Jul. 25 at 9:57 PM
$NKGN have not heard back from company. May still call one in but I guess I’ll have to risk the wait
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 24 at 7:53 PM
$NKGN well when you can only sell & not buy a stock we are witnessing the decline , sad
2 · Reply
Gj64
Gj64 Jul. 24 at 7:12 PM
$NKGN https://www.otcmarkets.com/stock/NKGN/quote#trade-data
0 · Reply
yup999
yup999 Jul. 24 at 6:09 PM
$NKGN Do not miss this one! As of June 2025 https://alsnewstoday.com/news/fda-clears-troculeucel-expanded-access-program/#:~:text=Expanded%20access%20program%20follows%20promising,6%20months%20of%20weekly%20treatments.
0 · Reply
yup999
yup999 Jul. 24 at 2:42 PM
$NKGN BREAKING NEWS https://www.stocktitan.net/news/NKGN/nk-gen-receives-fda-expanded-access-protocol-authorization-for-ab9xr1ljusng.html
0 · Reply